THERAPY DOSSIER · th-a80b8290ba2e

Probucol

Drug · ABCA1 inhibitor (INHIBITOR); antioxidant lipid-lowering agent

Review required. This record is flagged as borderline.

Evidence & regulatory context

Mechanism: ABCA1 inhibitor (INHIBITOR); antioxidant lipid-lowering agent
Target: ATP-binding cassette transporter ABCA1 (CHEMBL2362986)
Injury models: Other
Reported indication: Hypercholesterolaemia (antioxidant lipid-lowering agent; withdrawn from major Western markets, still marketed in Japan/China)
First approval: 1977
Development stage: Withdrawn from major markets for QT/cardiac safety (regional use persists)
ChEMBL record: CHEMBL608 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Probucol; Lorelco; Lurselle; Bisbid
Note: Not recorded

Clinical trials 5

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01031667 ↗PHASE4completed

Cilostazol and Probucol on Plaque Stabilization and Lesion Regression (SECURE)

Atherosclerosis

Enrolment: 118 · Results not recorded

NCT00426348 ↗PHASE4completed

Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy

IgA Nephropathy

Enrolment: 75 · Results not recorded

NCT01013532 ↗PHASE4unknown

Cilostazol vs Aspirin and Probucol in Ischemic Stroke Patients (Prevention of Hemorrhage/CV Events)

Brain Ischemia

Enrolment: 1600 · Results not recorded

NCT01726816 ↗PHASE2completed

Probucol in Patients With Nephropathy Due to Type 2 Diabetes

Diabetic Nephropathy

Enrolment: 126 · Results not recorded

NCT06931834 ↗Phase not recordedavailable

Expanded Access: R007 (Probucol) in Mitochondrial Disease and CKD

Mitochondrial Disease · Chronic Kidney Disease

Enrolment not recorded · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28384256 ↗2017Reported benefit

Probucol attenuates hyperoxia-induced lung injury in mice.

MouseOtherC57BL/6Femalen = 40 mice in total, 10 per group across four groups (room air…Intratracheal, delivered by IA-1C MicroSprayer130 micrograms per kg in 50 microlitres, equivalent to 100…Pre-treatment, given one day before the start of hyperoxia exposure

Model: Exposure to 95% oxygen for 72 h in a sealed chamber (hyperoxic lung injury as a model of acute respiratory distress syndrome)

Probucol significantly reduced total cells, macrophages, neutrophils and lymphocytes in bronchoalveolar lavage fluid, lowered IL-6, and improved the histological lung injury grade in hyperoxia-exposed mice. It reduced 8-hydroxy-2-deoxyguanosine staining and TUNEL-positive cell numbers, decreased p4…

Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…